Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methoxy poly(ethylene glycol)-poly(aspartate-nitroimidazole) micelles
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Methoxy poly(ethylene glycol)-poly(aspartate-nitroimidazole) micelles are hypoxia-responsive polymeric nanocarriers designed to enhance the efficacy of chemotherapy in solid tumors. The micelles are composed of a block copolymer featuring a hydrophilic methoxy poly(ethylene glycol) (mPEG) segment and a hydrophobic poly(aspartate) segment modified with nitroimidazole groups. In the hypoxic microenvironment of a tumor, the nitroimidazole moieties undergo bioreduction to hydrophilic aminoimidazoles, triggering micellar dissociation and the release of encapsulated therapeutic agents. Beyond acting as a delivery vehicle, the polymer carrier itself exerts a therapeutic effect by transiently depleting cellular reducing agents such as NADPH, glutathione (GSH), and thioredoxin. This depletion leads to the inactivation of NAD(P)H: quinone oxidoreductase 1 (NQO1), which normally stabilizes hypoxia-inducible factor-1 alpha (HIF-1α). By promoting the degradation of HIF-1α, these micelles sensitize hypoxic cancer cells to antineoplastic agents like sorafenib and overcome hypoxia-induced drug resistance.
- Other names
- methoxyl poly(ethylene glycol)-co-poly(aspartate-nitroimidazole) micellesmPEG-b-P(Asp-NI) micelles
02
Targets
NQO1HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on methoxy poly(ethylene glycol)-poly(aspartate-nitroimidazole) micelles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methoxy poly(ethylene glycol)-poly(aspartate-nitroimidazole) micelles.